Clinical Trials in Detroit

Showing 2961-2980 of 16,931 trials

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

NCT05938296

This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary efficacy of intratumoral injection of BS006 in patients with advanced solid tumors.

Solid Tumor

Binhui Biopharmaceutical Co., Ltd.29 participantsStarted Dec 2023

Orlando, Florida, United States • Detroit, Michigan, United States

RECRUITINGPhase 1< 1 mile

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

NCT06874335

This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.

Solid Tumor

Biohaven Therapeutics Ltd.95 participantsStarted Mar 2025

Denver, Colorado, United States • Lake Mary, Florida, United States • Detroit, Michigan, United States +9 more locations

Active Not RecruitingPhase 2< 1 mile

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

NCT02965716

This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.

Advanced MelanomaRecurrent MelanomaStage III Cutaneous Melanoma AJCC v7+5 more

National Cancer Institute (NCI)43 participantsStarted Jun 2018

Mobile, Alabama, United States • Goodyear, Arizona, United States • Los Angeles, California, United States +17 more locations

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Find Trials by Condition in Detroit

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Utilizing CT Based Imaging Parameters of Body Composition to Understand Heterogeneity of Response to Biologic Therapies in Severe Asthma Cohorts

LowSalt4Life: A Mobile Application to Reduce Sodium Intake And Blood Pressure

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

Randomized Comparison of PARtial Wrist Fusion With or Without Triquetral Excision (PARTE)

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

MARGetuximab Or Trastuzumab (MARGOT)

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer